Last reviewed · How we verify
Lucentis (Treat and extend)
Lucentis (Treat and extend) is a VEGF inhibitor (monoclonal antibody fragment) Small molecule drug developed by Retinal Consultants of Arizona. It is currently FDA-approved for Neovascular (wet) age-related macular degeneration, Macular edema following retinal vein occlusion, Diabetic macular edema.
Lucentis (ranibizumab) blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth and leakage in the retina.
Lucentis (ranibizumab) is used to treat conditions such as Wet Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion. It is administered in a treatment and extend regimen, which involves regular injections of the medication.
At a glance
| Generic name | Lucentis (Treat and extend) |
|---|---|
| Sponsor | Retinal Consultants of Arizona |
| Drug class | VEGF inhibitor (monoclonal antibody fragment) |
| Target | VEGF-A |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Ranibizumab is a recombinant humanized monoclonal antibody fragment that binds and neutralizes all active forms of VEGF-A, a key driver of pathological neovascularization and vascular permeability in retinal diseases. By inhibiting VEGF signaling, it reduces fluid accumulation in the macula and slows progression of vision loss. The 'treat and extend' regimen involves variable dosing intervals based on disease activity to optimize treatment burden and efficacy.
Approved indications
- Neovascular (wet) age-related macular degeneration
- Macular edema following retinal vein occlusion
- Diabetic macular edema
- Diabetic retinopathy
Common side effects
- Conjunctival hemorrhage
- Eye pain
- Floaters
- Intraocular pressure elevation
- Endophthalmitis
- Retinal detachment
Key clinical trials
- Extension Study for the Port Delivery System With Ranibizumab (Portal) (PHASE3)
- OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) (PHASE3)
- Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion (PHASE4)
- A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration (PHASE3)
- Rainbow Extension Study (PHASE3)
- Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation (PHASE4)
- Analysis of naïve Patients With Age-related Macular Degeneration Neovascular Type and Treated With Ranibizumab (Lucentis®) in Treat-and-extend at the CHU Brugmann.
- Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lucentis (Treat and extend) CI brief — competitive landscape report
- Lucentis (Treat and extend) updates RSS · CI watch RSS
- Retinal Consultants of Arizona portfolio CI
Frequently asked questions about Lucentis (Treat and extend)
What is Lucentis (Treat and extend)?
How does Lucentis (Treat and extend) work?
What is Lucentis (Treat and extend) used for?
Who makes Lucentis (Treat and extend)?
What drug class is Lucentis (Treat and extend) in?
What development phase is Lucentis (Treat and extend) in?
What are the side effects of Lucentis (Treat and extend)?
What does Lucentis (Treat and extend) target?
Related
- Drug class: All VEGF inhibitor (monoclonal antibody fragment) drugs
- Target: All drugs targeting VEGF-A
- Manufacturer: Retinal Consultants of Arizona — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Neovascular (wet) age-related macular degeneration
- Indication: Drugs for Macular edema following retinal vein occlusion
- Indication: Drugs for Diabetic macular edema
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing